OptimizeRx Statistics
Total Valuation
OptimizeRx has a market cap or net worth of $97.77 million. The enterprise value is $101.31 million.
| Market Cap | 97.77M |
| Enterprise Value | 101.31M |
Important Dates
The last earnings date was Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OptimizeRx has 18.77 million shares outstanding. The number of shares has increased by 3.83% in one year.
| Current Share Class | 18.77M |
| Shares Outstanding | 18.77M |
| Shares Change (YoY) | +3.83% |
| Shares Change (QoQ) | -3.20% |
| Owned by Insiders (%) | 14.83% |
| Owned by Institutions (%) | 70.80% |
| Float | 14.47M |
Valuation Ratios
The trailing PE ratio is 14.65 and the forward PE ratio is 5.76.
| PE Ratio | 14.65 |
| Forward PE | 5.76 |
| PS Ratio | 0.91 |
| Forward PS | 0.84 |
| PB Ratio | 0.75 |
| P/TBV Ratio | 5.15 |
| P/FCF Ratio | 6.82 |
| P/OCF Ratio | 6.80 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.37, with an EV/FCF ratio of 7.07.
| EV / Earnings | 14.82 |
| EV / Sales | 0.94 |
| EV / EBITDA | 5.37 |
| EV / EBIT | 6.96 |
| EV / FCF | 7.07 |
Financial Position
The company has a current ratio of 5.37, with a Debt / Equity ratio of 0.18.
| Current Ratio | 5.37 |
| Quick Ratio | 5.07 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | 1.24 |
| Debt / FCF | 1.65 |
| Interest Coverage | 2.83 |
Financial Efficiency
Return on equity (ROE) is 5.56% and return on invested capital (ROIC) is 7.87%.
| Return on Equity (ROE) | 5.56% |
| Return on Assets (ROA) | 5.43% |
| Return on Invested Capital (ROIC) | 7.87% |
| Return on Capital Employed (ROCE) | 9.28% |
| Weighted Average Cost of Capital (WACC) | 11.73% |
| Revenue Per Employee | $807,105 |
| Profits Per Employee | $51,398 |
| Employee Count | 133 |
| Asset Turnover | 0.64 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, OptimizeRx has paid $2.74 million in taxes.
| Income Tax | 2.74M |
| Effective Tax Rate | 28.63% |
Stock Price Statistics
The stock price has decreased by -48.47% in the last 52 weeks. The beta is 1.19, so OptimizeRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -48.47% |
| 50-Day Moving Average | 6.43 |
| 200-Day Moving Average | 12.75 |
| Relative Strength Index (RSI) | 34.36 |
| Average Volume (20 Days) | 544,633 |
Short Selling Information
The latest short interest is 2.16 million, so 11.53% of the outstanding shares have been sold short.
| Short Interest | 2.16M |
| Short Previous Month | 2.16M |
| Short % of Shares Out | 11.53% |
| Short % of Float | 14.94% |
| Short Ratio (days to cover) | 4.93 |
Income Statement
In the last 12 months, OptimizeRx had revenue of $107.35 million and earned $6.84 million in profits. Earnings per share was $0.36.
| Revenue | 107.35M |
| Gross Profit | 75.18M |
| Operating Income | 14.56M |
| Pretax Income | 9.58M |
| Net Income | 6.84M |
| EBITDA | 18.86M |
| EBIT | 14.56M |
| Earnings Per Share (EPS) | $0.36 |
Balance Sheet
The company has $20.17 million in cash and $23.72 million in debt, with a net cash position of -$3.55 million or -$0.19 per share.
| Cash & Cash Equivalents | 20.17M |
| Total Debt | 23.72M |
| Net Cash | -3.55M |
| Net Cash Per Share | -$0.19 |
| Equity (Book Value) | 129.61M |
| Book Value Per Share | 6.91 |
| Working Capital | 45.71M |
Cash Flow
In the last 12 months, operating cash flow was $14.38 million and capital expenditures -$52,000, giving a free cash flow of $14.33 million.
| Operating Cash Flow | 14.38M |
| Capital Expenditures | -52,000 |
| Depreciation & Amortization | 4.30M |
| Net Borrowing | -10.19M |
| Free Cash Flow | 14.33M |
| FCF Per Share | $0.76 |
Margins
Gross margin is 70.04%, with operating and profit margins of 13.56% and 6.37%.
| Gross Margin | 70.04% |
| Operating Margin | 13.56% |
| Pretax Margin | 8.92% |
| Profit Margin | 6.37% |
| EBITDA Margin | 17.57% |
| EBIT Margin | 13.56% |
| FCF Margin | 13.35% |
Dividends & Yields
OptimizeRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.83% |
| Shareholder Yield | -3.83% |
| Earnings Yield | 6.99% |
| FCF Yield | 14.66% |
Analyst Forecast
The average price target for OptimizeRx is $14.00, which is 168.71% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.00 |
| Price Target Difference | 168.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 14, 2018. It was a reverse split with a ratio of 1:3.
| Last Split Date | May 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:3 |
Scores
OptimizeRx has an Altman Z-Score of 4.49 and a Piotroski F-Score of 8.
| Altman Z-Score | 4.49 |
| Piotroski F-Score | 8 |